Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116904 | 0.78 | PTGS1 (0.44) | ESR1PTGS2PTGS1 | |
| SCHEMBL5117049 | 0.74 | ESR1 (0.66) | ESR1MIF | |
| SCHEMBL5851502 | 0.74 | ESR1 (0.56) | ESR1EBPSIGMAR1 | |
| SCHEMBL5852960 | 0.74 | ESR1 (0.56) | ESR1EBPSIGMAR1 | |
| SCHEMBL6438036 | 0.74 | ESR1 (0.41) | ESR1PTGS1 | |
| SCHEMBL6438035 | 0.74 | ESR1 (0.41) | ESR1PTGS1 | |
| SCHEMBL24360466 | 0.73 | CA2 (0.62) | CA1CA2CA9 | |
| SCHEMBL5532552 | 0.73 | CA2 (0.62) | CA1CA2CA9 | |
| SCHEMBL7805467 | 0.73 | ESR1 (0.57) | ESR1EBPSIGMAR1 | |
| SCHEMBL5851849 | 0.73 | ESR1 (0.55) | ESR1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7045540-B2 | Selective estrogen receptor modulators | BRISTOL MEYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050267183-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-12-01 | — | — | US | disclosed |
| US-20050245602-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-11-03 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245602-A1 | Selective estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885PTGS2 103/4885PTGS1 150/4885 |
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885PTGS2 102/4885PTGS1 48/4885 |
| US-20050267183-A1 | Selective estrogen receptor modulators | ESR2, ESR1, GPER1 | ESR1 2/4885PTGS2 150/4885PTGS1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.